Success Metrics

Completion Rate
0%(0/2)
Active Trials
5(50%)
Terminated
2(20%)

Phase Distribution

Ph phase_1
4
40%
Ph early_phase_1
1
10%
Ph phase_3
1
10%
Ph phase_2
4
40%

Phase Distribution

5

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(6)
Terminated(3)
Other(1)

Detailed Status

Active, not recruiting3
Recruiting2
Terminated2
Suspended1
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (10.0%)
Phase 14 (40.0%)
Phase 24 (40.0%)
Phase 31 (10.0%)

Trials by Status

suspended110%
not_yet_recruiting110%
withdrawn110%
recruiting220%
terminated220%
active_not_recruiting330%

Recent Activity

5 active trials
Showing 5 of 10
not_yet_recruitingphase_2

Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas

NCT07694089
suspendedphase_1

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

NCT05789589
recruitingearly_phase_1

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

NCT06831526
active_not_recruitingphase_1

Concurrent Azeliragon With Craniospinal Irradiation

NCT06724926
active_not_recruitingphase_2

Azeliragon in MGMT Unmethylated Glioblastoma

NCT05986851
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07694089Phase 2

Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas

Not Yet Recruiting
NCT05789589Phase 1

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Suspended
NCT06831526Early Phase 1

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Recruiting
NCT06724926Phase 1

Concurrent Azeliragon With Craniospinal Irradiation

Active Not Recruiting
NCT05986851Phase 2

Azeliragon in MGMT Unmethylated Glioblastoma

Active Not Recruiting
NCT05815485Phase 2

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

Active Not Recruiting
NCT05773664Phase 1

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

Withdrawn
NCT05766748Phase 1

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Recruiting
NCT03980730Phase 2

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Terminated
NCT02080364Phase 3

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

Terminated

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10